KRAS and cancer: Altogether, despite the continuous generation of more potent and selective inhibitors for KRAS G12C-mutant cancers, the current developmental landscape suggests that the progressive integration of G12C inhibitors into well-established treatment settings will represent the preferred path to maximize their therapeutic value.